Zydus receives approval from China’s NMPA for Venlafaxine Extended-Release Capsules, 75 mg and 150 mg

Zydus receives approval from China’s NMPA for Venlafaxine Extended-Release Capsules, 75 mg and 150 mg Ahmedabad, India, 11 November, 2025 Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received approval from the National Medical Products Administration (NMPA), China for Venlafaxine Extended-Release (ER) Capsules, 75 mg and 150 mg. Venlafaxine ER Capsules are indicated for the treatment of Major Depressive Disorder (MDD), Generalised Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder (PD). They help restore the balance of serotonin and norepinephrine in the brain to improve mood and reduce anxiety. Venlafaxine ER Capsules will be produced at Zydus’ manufacturing facility at Moraiya, Ahmedabad This is the first approval that the Group has received from NMPA in China.

The release as fetched from its publisher. zyduslife.com ↗